Researchers have developed MitoCatch, a novel system designed to deliver healthy mitochondria to specific, disease-affected cell types to treat mitochondrial dysfunction. While mitochondrial transplantation was previously possible, it lacked the precision and efficiency necessary to target specific cells; this new technology overcomes those hurdles by using protein binders to link donor organelles to target cell surfaces. The system employs three distinct strategies—monospecific binders on either the cell or the mitochondrion, and bispecific binders—to ensure versatile and effective delivery. Once internalized, these transplanted mitochondria move within the cytosol, associate with other organelles like the endoplasmic reticulum, and successfully undergo fission and fusion with the host’s native network. Experiments in human neurons, cardiac cells, and retinal tissue demonstrate that this method can rescue degenerating cells, including those from patients with optic nerve atrophy. Ultimately, MitoCatch represents a significant advancement in organelle therapy, offering a potential strategy for treating various currently untreatable neurodegenerative and metabolic disorders.
References:
- Ayupov T, Moreno-Juan V, Curtoni S, et al. Cell-type-targeted mitochondrial transplantation rescues cell degeneration[J]. Nature, 2026: 1-11.